Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia.
about
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaClinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemiaThe shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Emerging drugs for chronic lymphocytic leukaemia.Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia?The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy.Alemtuzumab in clinical practice: a British Columbia experience.Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemiaFirst-line treatment of chronic lymphocytic leukemia: role of alemtuzumab.Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.Ofatumumab, a human anti-CD20 monoclonal antibody.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioOutcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens.Predicting survival in chronic lymphocytic leukemia.Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.Allogeneic transplantation for chronic lymphocytic leukemiaOfatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.Chronic lymphocytic leukemia: treatment options for patients with refractory disease.Treatment of chronic lymphocytic leukemia with bendamustine in an HIV-infected patient on antiretroviral therapy: a case report and review of the literatureFinal results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia.Reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukaemia: related donor and umbilical cord allografting.Revisiting the role of hematopoietic stem cell transplantation in chronic lymphocytic leukemia.The evolving role of alemtuzumab in management of patients with CLL.Bendamustine for treatment of chronic lymphocytic leukemiaA phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.Alemtuzumab in CLL and other lymphoid neoplasms.Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia.Emerging therapy for chronic lymphocytic leukaemia.Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression.
P2860
Q24681296-BC790CC7-EB32-4B68-A179-4913636B0D49Q26783600-C0259617-C503-4D04-B31C-9871C7BA9B84Q30243968-F1EFEE5C-0358-4A03-B681-AD8099E54A64Q30353154-52A4B252-ABAE-4FDB-8AA8-911579740268Q30407633-5EEC3A4C-E122-4343-8AD3-E09F3E436739Q31033615-FBF4F375-1516-42A6-84E0-18BDD3A8E31AQ33365360-C78221BD-15CA-40DB-9D3F-85FA31B73EE9Q33378464-AAE8C4E5-21D7-4B26-97F7-72EC80423915Q33394487-D7AFC5F9-06C2-45D6-9C26-AAAB23DA839FQ33396594-18574169-F6E0-4B9B-87C3-FF88301F5CDCQ33396918-009F69D0-4EBA-4B97-839C-EAA4915353CDQ33429161-EAC4FF85-F1F3-4985-A329-FF229686D6A7Q33847401-999E0BDE-414B-4492-AB3F-144384B5EE0DQ33956034-40B0F9D8-317E-42DF-AC7D-4EE44744A7F5Q34008866-7C88E1DE-F467-4B28-9B76-2166B7CBCB1DQ34022228-DAA4235A-461A-4801-B98A-D021B889CB80Q34095311-7090C934-C315-487C-BEB9-4ADB7878924FQ34202277-C182CB05-0246-453A-9A9E-ECF8B7E656CBQ34240410-E4DBC3CD-4491-4D28-8189-12FD12697D00Q34257190-DA307944-790B-4218-AC88-DD8F82E3606DQ34324683-7D421908-0912-4684-9F75-DACF1369AB8AQ34549313-C1EF3349-2F6E-49A2-A6E1-2280105FE2B5Q34617307-D9FD97BA-98C0-42D4-92AD-D9139AE582BFQ35061729-0E50125B-1A01-4BC7-90B7-7DB9196717DCQ35136616-97CC845D-C06E-40F8-9655-DB52718449C6Q35382716-5D51F0EA-0609-48BD-9DCE-CF003E87FF27Q35841817-87D7C356-FAC6-4362-BA0E-9CE5092717E3Q36019515-8EDADA10-1AAD-414D-81C5-025D052ED944Q36065294-94E2BAC2-7374-4819-B89C-6B86E34D5DD4Q36092009-9791F1F4-1F4B-4132-B5B7-61A0950ACE7AQ36284521-C495E707-340D-421A-B4F0-5CB70C2DEF57Q36292883-B8934A75-DE33-4318-B031-3CDDC693F017Q36305762-B3A4DD08-CF7B-4C15-81A5-2BBCD7AB0812Q36519986-30089AEE-331E-4C32-A4E0-1D0DAD758C1EQ36654926-893007C9-BB27-4BD7-B34C-515BC03A27B2Q36659824-01094ED6-4FC6-4087-98AE-4453A44B229AQ36845282-DA823443-E2E3-4D0E-BA5D-DD628749DE5FQ36981738-341FF3AF-7439-4C93-8449-3D07555E06A1Q37027750-8E7B07D0-B1A7-490F-AF74-B9889DC0330CQ37032625-6BAA7334-807B-4470-AFAE-67BE0C2D478E
P2860
Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Results of first salvage thera ...... chronic lymphocytic leukemia.
@en
Results of first salvage thera ...... chronic lymphocytic leukemia.
@nl
type
label
Results of first salvage thera ...... chronic lymphocytic leukemia.
@en
Results of first salvage thera ...... chronic lymphocytic leukemia.
@nl
prefLabel
Results of first salvage thera ...... chronic lymphocytic leukemia.
@en
Results of first salvage thera ...... chronic lymphocytic leukemia.
@nl
P2093
P2860
P1433
P1476
Results of first salvage thera ...... chronic lymphocytic leukemia.
@en
P2093
Kantarjian H
Keating MJ
Kontoyiannis D
Plunkett W
P2860
P304
P356
10.1080/1042819021000006547
P577
2002-09-01T00:00:00Z